488 results on '"Minotti, Giorgio"'
Search Results
2. Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study
3. Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis
4. The cancer patient and cardiology.
5. Heart Failure in Long-Term Survivors of Childhood or Adolescent Cancers
6. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
7. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
8. LDL Cholesterol and Cardiovascular Events in a Population Network: One More Twist of an Endless Story
9. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology
10. Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis
11. Acute Heart Failure 29 Years After Treatment for Childhood Cancer
12. Sodium–Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials
13. Temporal patterns of left ventricular systolic and diastolic metrics changes in adult patients with haematological malignancies treated with chimeric antigen receptor (CAR)-T cells: results from the CARdio-Tox prospective study
14. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Heart Failure in China: a new pillar in our pockets, but at what price?
15. Anthracyclines and cardiotoxicity: Is CARP a forgotten biomarker?
16. Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock
17. Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
18. A Special Section on Clinical Pharmacology—Editorial
19. Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review
20. Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review
21. Temporal patterns of left ventricular systolic and diastolic metrics changes in adult patients with haematological malignancies treated with chimeric antigen receptor (CAR)-T cells: results from the CARdio-Tox prospective study.
22. Correction to: Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab
23. Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab
24. New Targeted Drugs for Acute Myeloid Leukemia and Antifungals: Pharmacokinetic Challenges and Opportunities
25. Ibrutinib and Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death
26. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion
27. Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study
28. Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review
29. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence
30. What is cardiotoxicity?
31. Cost-Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
32. Anthracyclins
33. Anthracycline Cardiotoxicity
34. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
35. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
36. Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment–Related Early Diastolic Dysfunction
37. From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction
38. Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox
39. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
40. Risk of Myocardial Infarction in Patients Treated With 5-Fluorouracil
41. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
42. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases
43. Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection
44. Report and Recommendations of the Workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity
45. Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis
46. Safety and tolerability of a novel oral nutritional supplement in healthy volunteers
47. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
48. An introduction to the metabolic determinants of anthracycline cardiotoxicity
49. Revisiting the Selective Vestibular Neurotomy for Intractable Ménière’s Disease in the Era of Endoscopy and Intraoperative Advanced Neuromonitoring
50. Quo Vadis COVID? Lessons from a Focus Topic Issue of Chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.